Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Tyk Medicines Inc. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners. Furthermore, the prosecution activity is spread across 2 distinct art units, which shows the examination environment for the company's current patent applications. This distribution indicates that the portfolio is reviewed by different specialized groups within the Biotechnology & Pharmaceuticals sector. Each matter requires a separate response strategy to address the specific technical requirements of the assigned divisions.
The busiest examiner for the portfolio is BURKETT, DANIEL JOHN, who is currently managing 1 busiest examiner pending office action. With 2 pending office actions in total, this examiner's workload represents a segment of the company's active office action count. The presence of 2 distinct art units and 2 distinct examiners suggests that the applicant must coordinate its prosecution strategy across multiple points of contact. Practitioners must manage the assigned officials to address the 2 pending office actions effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006493 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568761 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | BURKETT, DANIEL JOHN | 12d |
| 18006493 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568761 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | BURKETT, DANIEL JOHN | 1624 | §112 | Non-Final OA | 12d | Pending | Dec 08, 2023 |
| 18006493 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Non-Final OA | — | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial